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Summary 
 
Total body irradiation (TBI) is often used as part of the conditioning process prior to 
bone marrow transplants for diseases such as leukemia. By delivering radiation to 
the entire body, together with chemotherapy, tumour cells are killed and the patient is 
also immunosupressed. This reduces the risk of disease relapse and increases the 
chances of a successful implant respectively.  
 
TBI requires a large flat field of radiation to cover the entire body with a uniform dose. 
However, dose uniformity is a major challenge in TBI. (AAPM Report 17) The ICRU 
report 50 recommends that the dose range within the target volume remain in the 
range of  –5% to +7%.  Whilst it is generally accepted that this is not possible for TBI, 
it is normally clinically acceptable that ±10% of the prescribed dose to the whole body 
is sufficiently uniform, unless critical structures are being shielded.  
 
TBI involves complex dosimetry due to the large source to treatment axis distance 
(SAD), dose uniformity and flatness over the large field, bolus requirements, extra 
scatter from the bunker walls and floor and large field overshoot. There is also a lack 
of specialised treatment planning systems for TBI planning at extended SAD. 
 
TBI doses at Westmead Hospital are prescribed to midline. Corrections are made for 
variations in body contour and tissue density heterogeneity in the lungs using bolus 
material to increase dose uniformity along midline.   
 
Computed tomography (CT) data is imported into a treatment planning system. The 
CT gives information regarding tissue heterogeneity and patient contour. The 
treatment planning system uses this information to determine the dose distribution. 
Using the dose ratio between plans with and without heterogeneity correction the 
effective chest width can be calculated. The effective chest width is then used for 
calculating the treatment monitor units and bolus requirements.  
 
In this project the tissue heterogeneity corrections from two different treatment 
planning systems are compared for calculating the effective chest width. The 
treatment planning systems used were PinnacleTM, a 3D system that uses a 
convolution method to correct for tissue heterogeneity and calculate dose. The other 
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system, RadplanTM, is a 2D algorithm that corrects for tissue heterogeneity using a 
modified Batho method and calculates dose using the Bentley – Milan Algorithm. 
Other possible differences between the treatment planning systems are also 
discussed.  
 
An anthropomorphic phantom was modified during this project. The chest slices were 
replaced with PerspexTM slices that had different sized cork and PerspexTM inserts to 
simulate different lung sizes. This allowed the effects of different lung size on the 
heterogeneity correction to be analysed. The phantom was CT scanned and the 
information used for the treatment plans.  
 
For each treatment planning system and each phantom plans were made with and 
without heterogeneity corrections. For each phantom the ratio between the plans 
from each system was used to calculate the effective chest width. The effective chest 
width was then used to calculate the number of monitor units to be delivered.  
 
The calculated dose per monitor unit at the extended TBI distance for the effective 
chest width from each planning system is then verified using thermoluminescent 
dosimeters (TLDs) in the unmodified phantom. The original phantom was used for 
the verification measurements as it had special slots for TLDs.  
 
The isodose distributions produced by each planning system are then verified using 
measurements from Kodak EDR2 radiographic film in the anthropomorphic phantom 
at isocentre. Further film measurements are made at the extended TBI treatment 
SAD.  
 
It was found that only the width of the lungs made any significant difference to the 
heterogeneity correction for each treatment planning system. The height and depth of 
the lungs will affect the dose at the calculation point from changes to the scattered 
radiation within the volume. However, since the dose from scattered radiation is only 
a fraction of that from the primary beam, the change in dose was not found to be 
significant.   
 
This is because the calculation point was positioned in the middle of the lungs, so the 
height and depth of the lungs didn’t affect the dose at the calculation point.  
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 The dose per monitor unit calculated using the heterogeneity correction for each 
treatment planning system varied less than the accuracy of the TLD measurements. 
The isodose distributions measured by film showed reasonable agreement with those 
calculated by both treatment planning systems at isocentre and a more uniform 
distribution at the extended TBI treatment distance.  
 
The verification measurements showed that either treatment planning system could 
be used to calculate the heterogeneity correction and hence effective chest width for 
TBI treatment planning.  
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Chapter One – Introduction 
 
Radiation Oncology is a branch of medicine dedicated to the use of ionising radiation 
to destroy cancer cells.  For most cases, the cancer is a solid tumour and the 
radiation dose is delivered to the tumour and any likely sites of spread such as lymph 
nodes, as a localised treatment. Systemic treatments such as chemotherapy are also 
available. For systemic diseases such as leukaemia, localised treatment is not an 
option, as the entire body requires treatment.  
 
Part of the treatment available for diseases such as leukaemia is a bone marrow 
transplant (BMT). Total body irradiation (TBI) is a part of the treatment given prior to 
a bone marrow transplant. TBI involves the use of megavoltage photon beams to 
deliver radiation to the entire body. Historically gamma ray beams from a Cobalt – 60 
source were used but now linear accelerators are used for TBI throughout Australia. 
The radiation destroys the tumour cells and suppresses the immune system, 
reducing the risk of disease relapse and increasing the chance that the transplant will 
be successful.   
 
BMT success rates are such that “patients with acute myeloid leukemia transplanted 
in first remission can now expect an approximately 50 to 60% likelihood of long-term 
disease-free survival. Similar probabilities are also achievable after transplantation of 
adults with acute lymphoblastic leukemia in first remissions. Probability of relapse 
correlates with remission status at the time of the transplant, ranging from 20% in first 
remission to 60% with more advanced disease. Long-term survival for patients with 
chronic myelocytic leukemia who receive BMT in the phase of remission is 60 to 
70%”. (Merck Manual 2005) 
 
As with all radiation therapy the treatment process begins with collection of general 
linear accelerator data during commissioning, which is used for treatment planning. 
Then the patient data required for dose calculation is collected. This can involve 
physical measurements of patient size and contour, radiographic imaging and/or 
computed tomography (CT) scanning. How the patient will be positioned during 
treatment is also determined at this time, as well as the position of any accessories 
used during treatment, such as the beam spoiler. This process is known as patient 
simulation.  
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 The next stage for all radiation therapy treatments is known as treatment planning. 
During planning the beam arrangement and fluence is determined and the number of 
monitor units to be delivered so the prescribed dose to be given is calculated. 
Evaluation tools such as isodose map and dose volume histograms can be used to 
verify the target is receiving the correct dose and that organs at risk are receiving an 
acceptable dose, i.e. the dose to critical structures is as low as possible.  
 
Different methods can be used to calculate dose for radiation treatment. This thesis 
investigates whether there are any differences between two planning methods for 
TBI at extended distances. The two methods are a 2D planning Bentley – Milan 
algorithm with modified Batho heterogeneity correction method and 3D planning 
convolution method. This included testing any differences due to different lung sizes. 
The results were verified with thermoluminescent dosimeters (TLD) and film 
measurements in an anthropomorphic phantom.  
 
Anthropomorphic phantoms can be used to verify the dose distribution and absolute 
doses at points predicted by treatment planning systems. These measurements are 
made using ionising radiation detectors such as radiographic film and TLDs. This 
verification process evaluates the different methods of calculating dose for radiation 
treatment.  
 
Only after the accuracy of a dose calculation method has been verified with such 
measured data can this method be used to calculate the number of monitor units for 
each beam of a patient treatment.  
 
During treatment the patient is setup the same way as they were positioned during 
the patient simulation process and the treatment is delivered as planned. Invivo 
dosimetry, where measurements are made with detectors on or inside the patient 
during treatment, is another verification method. Invivo dosimetry can be used to 
determine the accuracy of the entire treatment chain from simulation to treatment as 
described above.  
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In chapter two a literature review is completed, to give a background to this research 
project. This begins by covering the clinical aspects of TBI, including the short term 
and long term side effects of TBI.  
 
Some of the methods used for delivering TBI are discussed in chapter two, including 
the requirements of the delivery systems. The various methods for tissue 
compensation such as bolus material or metal compensators are also discussed. 
These can either compensate for variations in patient shape or for low density 
regions, to ensure the same effective pathlength to the patient’s midline.  
  
For radiation therapy treatment planning to occur, parameters about the treatment 
beam, such as its profile and percentage depth dose curve, as well various factors 
related to beam scatter need to be determined. The beam data required for TBI 
treatment planning is discussed.  
 
Methods for planning TBI treatment are discussed, including tissue density 
heterogeneity corrections. The algorithms used by both treatment planning systems 
for calculating radiation dose are also described. Factors that influence the overall 
dose distribution and more specifically lung dosimetry during TBI are also discussed. 
The lung is of particular interest because lung tissue has a lower density than muscle 
tissue so offers less attenuation to radiation, affecting the dosimetry. Lung tissue is 
also radiation sensitive as demonstrated by one of most serious morbidities from TBI, 
radiation pneumonitis. 
 
Methods for verifying the calculated dose are also described. Some of the 
characteristics of TLDs and films, two of the most commonly used dosimeters for 
verification measurements, are also discussed.  
 
In chapter three the project methodology is discussed. A phantom was designed by 
modifying an anthropomorphic phantom with a specially developed chest insert to 
replace the original phantom chest slices. This enabled different lung sizes to be 
simulated.  This phantom was then scanned with its different lung sizes.  
 
The CT datasets were then used to create plans for the various different lung sizes. 
RadplanTM calculates dose using the Bentley – Milan algorithm and corrects for 
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heterogeneities using a modified Batho technique. PinnacleTM (ADAC laboratories, 
Milpitas, CA) uses a convolution method to calculate dose distributions.  
 
For each treatment planning system the plans were repeated without tissue 
heterogeneity corrections. The ratio between the plan with heterogeneity correction 
and without for each system was then used to calculate the effective chest width. The 
effective chest width was then used to calculate the number of monitor unitFs.   
 
To verify the planning processes worked as expected, plans were made using the 
unmodified RANDOTM phantom with TLD slots. The planned point doses were 
verified by placing TLDs within the phantom and delivering a treatment at the 
extended TBI SAD of 400 cm to the phantom as planned. Comparisons were made 
between the measured dose and the planned dose.  
 
Kodak EDR2 radiographic film was also placed into the phantom to measure the 
delivered dose distribution. This measured dose distribution was then compared to 
the planned dose distributions from each planning system. This process was 
repeated at 100 cm SAD (isocentre) and the extended TBI treatment distance of 400 
cm. 
 
Chapter four presents the results calculated using data from the treatment planning 
systems. The effective chest width is calculated using the ratio between the monitor 
units from the treatment planning systems with and without heterogeneity correction. 
The dose per monitor unit verification measurements with TLDs and dose distribution 
verification measurements with radiographic film are also presented.  
 
Chapter five discusses the results of the planning studies and the phantom 
verification measurements. It also discusses the errors and uncertainties pertaining 
to this study and clinical TBI treatments. Suggestions are made for future work.  
 
Chapter six offers the conclusions of the study. Whilst a difference was calculated, 
this difference was smaller than the accuracy of the TLD measurements. Hence no 
significant difference could be detected between the two planning methods. The film 
measurements showed reasonable agreement with both planning systems at 100 cm 
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SAD and significant differences at 400 cm SAD. Either method could be used 
clinically.  
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Chapter Two – Literature Review 
 
Clinical Aspects 
 
TBI with megavoltage photon beams is a radiotherapeutic procedure that is used for 
the treatment of haematological disorders and disseminated malignancies such as 
acute leukaemia, lymphomas or aplastic anaemia. It is part of the cytoreductive 
conditioning program prior to a bone marrow or stem cell transplants, along with 
chemotherapy. (AAPM report 17; Harden, 2001) 
 
TBI helps remove tumour cells from the body and also results in adequate 
immunosuppression for a successful graft. (Galvin, 1980; Kim, 1980) This is due to 
the ablation of normal hemopoietic and lymphoid cells, which helps facilitate 
engraftment of the new cells. With TBI treatments there are no sanctuary sites (due 
to radiation penetration throughout entire body) or evolution of clonal resistance. It is 
also likely that chemoresistant leukemic cells will remain radiosensitive (Doughty, 
1987). 
 
As with all treatment modalities, it is desirable to have the maximum possible 
therapeutic ratio, ie, high disease control with minimal normal tissue toxicity, 
especially to critical tissues. (Obcemea, 1992)  
 
Short-term side effects of TBI include mucositis, alopecia, dysphagia, diarrhoea, 
parotitis, erythema, pneumonitis, veno-occlusive disease and all the attendant risks 
of prolonged pancytopaenia. The long-term risks include ophthalmological sequelae 
(cataracts), endocrinological sequelae (reduced pituitary function), neurological 
sequelae, infertility and increased risk of secondary malignancies. (Harden, 2001; 
Quast, 1987) Following the BMT there is also a risk of graft versus host disease. 
(Yuille, 1983) The dose tolerance of various different normal tissues for non-
stochastic radiation effects is discussed in the ICRP report 44.  
 
TBI was originally given as a single fraction (Harden, 2001) but side effects can be 
reduced with fractionated treatments, based on radiobiology principles of preferential 
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normal tissue repair. Studies have found that fractionated TBI can reduce side effects 
whilst still producing good anti-leukemic outcomes. (Cosset, 1994; Shank, 1983)  
 
Dose uniformity is a major challenge in TBI. (AAPM Report 17) Under-dosages will 
increase the risk of relapse whilst overdose, especially to critical organs (lungs, eye 
lens etc), will increase toxicity. According to the ICRU report 50 the dose range within 
the target volume should remain in the range of –5% to +7%. So for TBI the ideal 
situation is that the whole body including the skin receives a dose within –5% and 
+7% of the prescribed dose.  Whilst it is generally accepted that this is not possible 
for TBI , the effect on the clinical outcome is not known. (Galvin, 1980; Vollans, 2000) 
Typically ±10% of the prescribed dose to the whole body provides clinically 
acceptable dose uniformity, with the possible exception of the extremities and other 
non-critical structures. (Khan, 2003) 
 
Prescriptions tend to be in the range of 5 to 14 Gy, in up to 8 fractions, often treated 
twice daily. TBI reduces the number of malignant stem cells by a factor of 10 for each 
1.5 to 2 Gy. (Quast, 1987) ICRU 29 recommends a prescription point as being 
central and at a depth of half the patient’s thickness. The prescription point when 
used will typically be in the abdominal or pelvis region (Sanchez-Doblano, 1995), 
such as the midpoint at the umbilicus level (Syh, 1992). Sometimes the prescription 
will be to the entire midline or midplane. (Kim, 1980) Sometimes a lower dose rate of 
5 – 10 cGy per minute at the prescription point is used. (AAPM report 17)  
 
Radiation dose rate and fractionation schedule can affect the incidence of radiation 
pneumonitis and need to be considered in the prescription. (Yuille, 1983) Dose limits 
are sometimes prescribed to critical organs such as the lungs, for example, 9.6 Gy to 
the lungs when the whole body doseprescription was 12 Gy. (Sanchez-Doblano, 
1995, Svahn-Tapper, 1990))  
 
Most data for radiation syndromes come from nuclear incidents and are therefore 
from a single exposure. For TBI the patient will suffer from bone marrow (or 
hemopoietic) syndrome. The dose should however be low enough to not cause any 
concern regarding gastrointestinal or central nervous system syndromes. Following a 
TBI treatment, patients can survive only if they receive a BMT.  
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 TBI Delivery Techniques 
 
There is no generally accepted technique for delivering TBI. Factors that may 
influence the way in which TBI patients are treated include the size of the treatment 
room, energy of the linear accelerator and availability of another linear accelerator as 
a back up machine. Some centres have dedicated large field TBI irradiators in 
specially designed treatment rooms but most use standard radiotherapy accelerators 
for TBI. (Curran, 1989; Podgorsak, 1985; AAPM report 17) Some use single sources 
of radiation, others dual (Obcemea, 1992) or multiple sources from different 
directions (Sanchez-Doblano, 1995, AAPM report 17).  
 
If using a single radiation source, such as one accelerator in a bunker, either 2 field 
or 4 field techniques have been used to deliver TBI (Vollans, 2000). For the two field 
techniques, they can be either opposed bilateral or anterior/posterior. 
Anterior/posterior treatments are delivered with the patient in a sitting or standing 
position (Harden, 2001) or lying on their side. For bilateral techniques the patient is 
usually supine either lying flat or semi-reclined, often with legs flexed to reduce the 
patient’s length to fit in the field. Four field techniques involve anterior, posterior and 
bilateral fields. Diagram 2.1 shows some of the delivery techniques used for TBI.  
 
TBI requires the use of a very large, uniform high-energy photon beam so the entire 
body receives a uniform dose. To get such a large field size, the principle of 
geometric beam divergence from the source is applied. In order to get a treatment 
field large enough to treat the entire body, source to axis distances (SADs) of 3 – 5 m 
are used. (Thomas, 1990) 
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Diagram 2.1 – Shows some of the delivery techniques available for TBI. (Sourced 
from AAPM report 17) 
 
Various different photon energies are used for TBI, from gamma rays from a cobalt-
60 teletherapy units (1.25 MeV) through to linear accelerator beams from 4 MV to 25 
MV. (Sanchez-Doblano, 1995) Cobalt-60 Teletherapy units are no longer used for 
radiotherapy treatment delivery in Australia. For lateral treatments higher energies (ie 
10 MV or higher) are preferred for delivering a more uniform dose distribution as the 
beam needs to travel through the pelvis and shoulder regions. However, for AP/PA 
treatments, 6 MV beams provide less undesirable high dose regions in the lungs. 
(Ekstrand, 1997) 
 
Linear accelerators use high frequency electromagnetic waves to accelerate 
electrons through a linear accelerating tube. To produce an x-ray photon beam these 
electrons hit a target made of a high Z material such as tungsten, producing 
bremsstrahlung x-rays. Following the target, the beam intensity is modified by a  
flattening filter.  The target is thick enough to absorb most of the electrons. The beam 
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then passes through two independent ion chambers, which monitor beam output and 
symmetry. Finally the beam is collimated.   
 
There are also other techniques that use multiple parallel and adjacent beams or 
moving beams or patient translation. (Sanchez-Doblano, 1995) These are often 
applied if a smaller treatment distance is available. Adjacent beams from a single 
accelerator, such as in diagram 2.1j, create concerns regarding complex dosimetry at 
field junctions and circulating cells potentially receiving a reduced dose. Using field 
junctions can also cause concern of hot spots if the beam overlap at the junction or 
cold spots if there is a gap at the junction. (Rider, 1983) 
 
To achieve a treatment field 2 m long an SAD of 5 m is required. To ensure the 
patient remains in the field the collimator is rotated through 45° with the jaws opened 
to the maximum aperture (usually 40 x 40 cm at 100 cm SAD). (Harden, 2001) The 
TBI treatment SAD can be marked with a laser line which can be aligned to patient 
midline to aid setup to treatment SAD. (Svahn-Tapper, 1990)  
 
A low atomic number absorber (such as a PerspexTM screen) is often placed in front 
of the patient, acting as a beam spoiler. This reduces the dose build up region. This 
improves the dose distribution to the skin, making it more similar to the prescribed 
dose. For a 10 mm spoiler placed 15 cm in front of the patient with a beam spoiler 
correction factor applied at a depth of 5 cm, the depth dose increased by only 1% at 
2 cm depth. At larger depths the spoiler was found not to influence the depth dose 
values. (Svahn-Tapper, 1990) The surface dose also increases as beam energy 
decreases, the distance between the spoiler and the patient decreases and with 
increasing spoiler thickness (towards depth dose max). A 1 cm thick PerspexTM beam 
spoiler for a 10 MV photon beam will increase the skin dose up to 97% of dmax. 
(Sanchez-Nieto, 1997) The required thickness of the beam spoiler is dependent upon 
the energy of the beam, as the position of the dmax changes with beam energy. 
However the clinical effects of skin dose is not known as no systematic study has 
been completed analysing this. (Kim, 1980) 
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Tissue Compensation 
 
Some centres do not use any compensation for irregularities in patient shape. 
(Vollans, 2000) If missing tissue due to contour variations of the patient is to be 
accounted for, this can be achieved using either missing tissue compensators or 
tissue-equivalent bolus. These compensators provide greater dose uniformity along 
the body by reducing the irregularity of the body thickness. (Khan, 2003; Galvin, 
1980; Khan, 1980. The compensators are placed between the source and the 
patient, either in the accessory mount or are mounted onto the beam spoiler.  
 
Bolus material placed around the patient for TBI needs to be malleable and be able 
to hold a shape at room temperature, as well having a density that is soft tissue 
equivalent. Strictly this refers to electron density, but physical density can be used 
satisfactorily as an approximate measure of electron density for low Z materials. 
Materials such as rice or bicarbonate soda are not quite as dense as tissue (AAPM 
report 17) but in small bags make suitable bolus materials, although it can be hard to 
control the thickness. One group designed bolus by making a compound of soft 
paraffin and acrylic granules, sealed in thin elastic polyurethane bags. This then has 
a putty type consistency. (Doughty, 1987) Various commercial tissue equivalent 
bolus materials are also available.  Bolus material can also be added under the legs 
where it not only provides extra scatter but also provides support for the patient. 
(Yuille, 1983) Missing tissue compensators of lead or copper can also be designed. 
(Galvin, 1980) The position of the compensators can be verified with film. (Quast, 
1987) 
 
Beam Data 
 
Treatment planning systems require beam data to be measured and inputted in order 
to calculate the dose distributions for treatments. Consideration needs to be given to 
the different geometry and scatter conditions for TBI when the beam data 
measurements are being made. It may not be acceptable to simply extrapolate small 
field data or data measured at isocentre. When using an ion chamber for beam data 
measurements, care should be taken regarding cable and stem irradiation effects, as 
the radiation field can cause extra current to be induced in the cable, changing the 
measured current. This is of particular concern in TBI due to the large field sizes 
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used which can mean larger lengths of cable being irradiated during measurements.  
(Fiorino, 2000).  
 
Most linear accelerator monitor unit ion chambers are absolutely calibrated to provide 
a machine output of 1.0 cGy/monitor unit at machine isocentre under reference 
conditions. Absolute calibration is done following certain protocols such as the IAEA 
TRS 398, traceable back to primary standards. For the IAEA TRS 398 protocol, the 
reference conditions for 6 MV photon beams are to use water as the phantom 
material, a cylindrical ionization chamber with the reference point on the central axis 
of the chamber, a measurement depth of 10 g cm-1, a source to chamber distance of 
100 cm and a field size of 10 cm x 10 cm. However, some centres use the dose rate 
or an output factor at the extended SAD for treatment planning for TBI (Abraham, 
2000).  Dose is defined as “the energy absorbed from ionizing radiation per unit 
mass” and has the unit of Gray (Gy). (Johns, 1983) 
 
Output factors can be measured to determine the monitor units for extended 
distances. This would require variations based on patient size and could be used to 
calculate Tissue Phantom Ratios (TPR) and/or Tissue Maximum Ratios (TMRs). 
However, as discussed below TMR values vary less than 1.5% for the extended SSD 
compared to isocentric treatments so dose rate calibrations can also be transferred 
to extended TBI SSDs. (Khan, 1994) 
 
A TPR is defined as the ratio of absorbed dose at any given depth to the dose at the 
same point at a fixed reference depth, achieved by changing the source to surface 
distance. A TMR is defined the same way as TPR except the reference depth is the 
depth of maximum dose. The setup arrangement for measurements of TMR and TPR 
are shown in diagram 2.2. 
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Diagram 2.2 – Setup arrangement for measurement of TPR and TMR, where d is any 
given depth and dref is a fixed reference depth for TPR measurements and dmax for 
TMR measurements. 
 
Output factors at extended distance have been measured and the largest difference 
between the smallest phantom (20 x 20 cm) and largest “infinite” phantom (50 x 140  
cm) was found to be 2.4% for a 6 MV beam, implying the phantom size within the 
large radiation field has a minimum effect on dose rate at the reference point. 
(Podgorsak, 1985) 
 
TBI requires a beam that covers the entire patient with an adequately flat, uniform 
beam. As the collimator is often rotated to 45° for TBI the profile is that of a diagonal, 
which may also affect beam flatness. The TBI beam profile in the gun-target direction 
should be measured in air, as it is the primary radiation component that is to be 
measured, not scattered radiation. The beam uniformity decreases as SAD 
increases. The useful treatment field is that which is within the 94% isodose curve 
(Sanchez-Nieto, 1997). The dose profile may also include backscattered radiation 
from the wall.  
 
Varian Linear Accelerators come with flattening filter, which is a cone shaped 
attenuator. This filter is designed to produce optimal flatness at 10 cm depth for 100 
cm SSD. For shallower depths and along the beam diagonals, there will be an 
overflattening affect, seen as “horns” on a beam profile. For TBI, these horns will be 
over the body extremities, (head and feet) which may results in some dose 
enhancements in these areas. This problem was reduced at one institution by the 
addition of an extra TBI flattening filter. (Doughty, 1987) 
 
Dose ratio data such as Percentage Depth Dose (PDD), TPR or TMR data should be 
measured at the centre axis and at various off axis points, such as at the level of the 
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lungs.  PDD data varies with patient thickness due to changes in backscatter 
(Abraham, 2000, Sanchez-Nieto, 1993, Podgorsak, 1985). The PDD can be 
corrected using a Backscatter Correction Factor (BCF) and Lateral Scatter Correction 
Factor (LCF). The BCF corrects for lack of backscatter by applying a ratio of the PDD 
with limited backscatter versus the PDD at the same point if there was infinite 
backscatter. Hence as backscatter thickness increases towards an infinite thickness, 
the exponential increase in backscatter tends to 1, due its definition.  However, the 
BCF is linear for depth as the probability of backscatter increases with the depth of 
the point of measurement.   
 
For TBI treatments close to the bunker wall, back scattered radiation from the wall as 
well the patient can be seen. For smaller phantoms midline dose will be influenced 
more by backscattered radiation from the wall than for larger phantoms, which should 
be considered when choosing a phantom. (Svahn-Tapper, 1990) 
 
Similarly the LCF is the ratio between a PDD at a certain point for a given cross 
section versus the PDD at the point for an infinite cross section giving full lateral 
scatter. As with the BCF, the LCF has linear variation with depth and exponential 
variation with distance to lateral surfaces, which tends to 1 as the thickness tends 
towards full lateral scatter conditions (ie almost infinite distances to the lateral 
surface, providing almost infinite lateral scatter).   
 
As the SAD increases, the PDD shifts due to the inverse square law (Metcalfe, 
1997). Not considering the deviation from the Inverse Square Law (ISL) due to 
changed scatter conditions, the PDD at extended distances can be approximated 
using the Mayneord Factor. (AAPM report 17, Mayneord 1994) Data calculated from 
100 cm SSD data using the Mayneord factor has been compared to SSD data 
measured at TBI treatment SSD  (in this case 455 cm) with TBI scatter conditions. 
The measured and calculated data agreed to within 2.5% for several depths from 5 
cm to 30 cm. (Sanchez-Nieto, 1993) This error can be as large as 6%. (AAPM report 
17) Therefore measurements should be made to confirm any conversions if needed 
in large beam geometry at treatment SSD.  
 
Off axis TMR measurements can be normalised to central axis TMR measurements. 
It has been found that for TMR 35 cm and 70 cm off axis the difference between 
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central axis and off axis TMRs are 1% and 4-5% respectively for large depths. 
(Svahn-Tapper, 1990) This is due to changes in the energy spectrum across the 
beam. For TBI this means that central axis TMR measurements are not valid in the 
distal head and feet regions.  
 
Collimator scatter factors (CSF) correct for the difference between the field size at 
calibration (typically  10 cm x 10 cm) with the treatment field size, due to changes in 
scatter within the linear accelerator head. The collimator scatter factor at TBI SSD 
should not vary much compared to the data measured at isocentre. The data at the 
two distances for field sizes larger than 25 cm x 25 cm has been found to be within 
0.3% with up to 1% variation for field sizes of 10 cm x 10 cm. (Smith, 1996, Curran, 
1989) Because the jaws are always set to 40 cm x 40 cm for TBI, this will not vary 
significantly between the two distances. CSF can be measured with an ion chamber 
in air with a cylindrical build up cap providing a build-up depth for the photon energy 
being used.  
 
The peak scatter factor (PSF) corrects for changes in the phantom for the treatment 
field size as compared to the 10 cm x 10 cm field used for calibration. For 
conventional radiotherapy, the phantoms used to measure the data are normally 
larger than the radiation field. However, for TBI this is not the case, but rather the 
phantom is significantly smaller then the radiation field. This may affect the TMR and 
PSF values for TBI. The changes for PSF depend on energy but will vary less then 
1%. The TMRs have been found to vary by less 1.5%. (Curran, 1989, Khan, 1980) 
 
Due to scattered radiation from the bunker walls, floor and linear accelerator head, 
discrepancies may be seen if the ISL is used to calculate the dose rate at the TBI 
treatment SAD. (AAPM report 17, Rider, 1983, Van Dyk, 1987) The deviation 
between the inverse square law and measured data increases with distance from the 
reference. This deviation from the ISL can be fitted as a four-order polynomial, with 
an error between measured and calculated data of less than 0.08%. (Sanchez-Nieto, 
1997) This must also be considered in terms of the different source to point distances 
within the body (Sanchez-Doblano, 1995). Other investigations have shown no 
systematic deviation from the inverse square law when it is measured on the central 
axis at various depths in a 30 cm3 phantom at SSD of 430 cm. (Svahn-Tapper, 1990) 
Other investigations found that the inverse square predicted the measured dose to 
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within 1.5% for a variety of energies and distances. (Curran, 1989) However 
deviations of up to 6% have been reported (Quast, 1987). 
 
For TBI treatments, the equivalent square of the frontal side of the patient (from the 
beam’s eye view) should be used for the field size when calculating the TMR and 
PSF values as opposed to the jaw opening size. (Curran, 1989) This is because the 
field size is larger then the scattering volume. This is particularly important for TMR. 
The area over perimeter method is an adequate method for calculating the equivalent 
square for TBI. (Podgorsak, 1985) Ideally when beam data measurements are being 
made the phantom should be of similar equivalent square size to the patient so that 
errors can be minimised. (Kirby, 1988) 
 
Treatment Planning 
 
Currently there is no commercially available treatment planning system for TBI. 
Planning for TBI typically entails calculating at least one point dose. The total dose at 
any point is the sum of the primary beam plus scattered radiation.  
 
For manual calculations, the thickness of the body in the beam direction needs to be 
determined at each reference point. This data is available from CT measurements 
but mechanical measurements are an alternative. (Quast, 1987) An effective depth 
that corrects for tissue density heterogeneities can also be used in manual 
calculations. This is especially important for points near the lungs. 
 
Some centres have also developed in house TBI treatment planning systems, using 
x-ray computed tomography (CT) data. (Sanchez-Nieto, 1997) CT scans provide 
anatomical information as well as density heterogeneity information. Considering the 
patient’s physical parameters and anatomy can optimise the dose distribution in the 
patient. (De Sapio, 1990, Quast, 1986).   
 
To use the density heterogeneity information from a CT scan, the CT numbers need 
to be calibrated to physical electron densities using an electron density calibration 
phantom. Radiotherapy treatment planning systems use data tables to assign an 
electron density to each pixel’s CT number or Hounsfield Unit, which is based on the 
gray scale.  (Khan 2003) 
 16
 However, since at the megavoltage energies used for radiotherapy the Compton 
effect is the dominant photon interaction, it is the electron density (number of 
electrons per cm3 multiplied by mass density) of a material that has the most effect on 
beam attenuation. However, since the number of electrons per gram of material is 
very similar for many materials,  (Khan, 1994) the mass density of a material may 
also be used for calculating the heterogeneity corrections. 
 
There are different methods for correcting for tissue density heterogeneities. These 
methods vary from simple corrections that only correct for changes in the fluence of 
the primary photon beam through to convolution methods, which also account for 
scattered radiation and electron transport. Monte Carlo simulations are the most 
accurate method but require long computational periods that are currently 
impractical.  
 
The effective depth can be calculated by multiplying assumed heterogeneity 
correction factors for lungs by the patient’s measurements for planning purposes. 
(Vollans, 2000)  
 
deff = d – (ρrel lung x dlung)    (1) 
 
 
Where deff  is the effective depth 
 
 d is the physical depth 
 
 ρrel lung is the relative density of the lung tissue 
 
 dlung is the physical depth taken by lung tissue 
 
Lung density can vary between 0.15 g/cc to 0.4 g/cc as compared to water at 1.0 
g/cc so heterogeneity corrections are important. By studying layered lung geometry 
another investigator has found that for lung density 0.31 g/cc, a lung correction factor 
of about 1.5% per centimetre of lung tissue has been found to be necessary, and that 
this holds for both calculations and measurements. (Obcemea, 1992) 
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 Another method uses a ratio of TARs for the physical and effective depths. (Metcalfe, 
1997) This method does not take into account the relative position of the 
inhomogeneity, the lateral extent of the structure or electron transport. (El-Khatib, 
1986)  
 
The Batho power law method uses TARs raised to an exponent, which depends on 
tissue density. Batho originally introduced this method for calculating doses beyond a 
single inhomogeneity. (Batho, 1964) This method was then extended to include 
doses within the inhomogeneity (Sontag, 1991) and to calculate for a number of 
inhomogeneities (Webb, 1979). This algorithm implicitly considers scattered 
radiation. (Metcalfe, 1997) This method considers the relative position of the 
structure. (El-Khatib, 1986) It can account for the lateral extent of the inhomogeneity 
if scatter summation is also applied. (El-Khatib, 1986, Lulu, 1982) It does not 
consider secondary electron transport. (El-Khatib, 1986)  
 
 
 
 
 
 
 
 
 
Diagram 2.3 – Setup for Batho density correction. 
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Where CF is the correction factor  
 
 d1 and d2 are the depths are shown in diagram 2.3 
 
 f is the field size 
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 ρe is the density of the lung tissue 
 
For a single layered heterogeneity with a less than unit density, the dose is 
underestimated within the low density region, with the largest errors near the top of 
the heterogeneity. However the method shows good experimental agreement below 
the heterogeneity. This method generally works well for smaller fields but the larger 
the field the larger the error, due to the increase in scatter affecting the percentage 
depth dose curve. (Metcalfe, 1997) 
 
The equivalent TAR method uses multi slice CT information to account for scattered 
radiation. It uses ratios of TARs depending on effective beam radius (to account for 
scattered radiation) and effective depth (correcting for primary beam).  (Metcalfe, 
1997) This method considers the relative position of the inhomogeneity and the 
lateral extent of the inhomogeneity but does not consider secondary electron 
transport. (El-Khatib, 1986) In comparison with measured data (when the field is 
large enough for electronic equilibrium) this method gives accurate results, which 
implies that it adequately models scatter dose. (Metcalfe, 1997) 
 
The differential Scatter-Air Ratio method takes the primary dose and then adds 
scatter radiation. The scatter can be calculated either assuming homogeneity or 
correcting for heterogeneity by considering the attenuation of the primary beam for 
each scatter element or including the attenuation of scattered photons in their path to 
the calculation site. (Metcalfe, 1997) This method considers the relative position of 
the inhomogeneity and the lateral extent of the inhomogeneity but does not consider 
secondary electron transport. (El-Khatib, 1986) A similar method is the delta volume 
method. (Metcalfe, 1997) 
 
Although these methods can calculate the effect of inhomogeneities on photon 
fluence they cannot predict changes to secondary electron transport. However, when 
electronic equilibrium exists, electron transport can be ignored. Therefore, when 
electronic equilibrium exists these methods are more accurate as the change in dose 
is proportional to primary photon fluence. (Metcalfe, 1997) 
 
Computerised planning systems used for non-TBI radiotherapy planning can assist in 
TBI treatment planning, including calculating lung inhomogeneity corrections. The 
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two types of computer system used in this project are based on the 2D Bentley – 
Milan algorithm (Milan, 1974) with modified Batho inhomogeneity corrections 
(RadplanTM) and 3D convolution model (PinnacleTM, ADAC Laboratories, Milpitas 
CA).  
 
The Bentley – Milan algorithm for dose calculation accounts for patient contour 
variations and different SSDs. (Milan, 1974; Storchi, 1996; Metcalfe, 1997) The 
algorithm makes use of measured central axis PDD and beam profiles. The beam 
data is measured for different square field sizes and profiles are measured at 
different depths.  
 
The beam data is entered into the computer as 47 fanlines. The central fanline, on 
central axis, contains 17 PDD points. There are then 23 fanlines off axis on each side 
of the central fanline. The profiles are normalised to 1.0 on the central axis and then 
multiplied by the PDD value at the depth of the profile. Thus the fanline grid gives 
information regarding the increasing geometrical penumbra with depth and changes 
to the scatter dose. The algorithm interpolates within the fanline grid for dose 
calculation.  
 
The general Bentley – Milan algorithm is: 
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Where D is the dose 
 
 d is the depth 
 
 R is the off axis ratio 
 
 y is the off-axis distance 
 
 f is the field size 
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y’ is the projected off axis distance at the reference SSD for patient contour 
variations. 
 
Investigations have been completed to evaluate using the ADAC PinnacleTM 
treatment planning system for TBI planning. (Abraham, 2000) This paper first 
investigated the heterogeneity corrections calculated by PinnacleTM at the isocentre 
level (100 cm SAD). This was completed by comparing film dosimetry with calculated 
data. They then placed the RANDOTM anthropomorphic phantom at the extended 
SSD for TBI set-ups and exposed two films and compared these films to the 
calculations from PinnacleTM. 
 
Diagram 2.5 shows the basic geometry used for a convolution method. Convolution 
methods involve two components: TERMA, which represents the total energy 
imparted into the medium by interactions of primary photons and a kernel, which 
represents energy deposited around a primary interaction site at vectorial 
displacements, as a fraction of TERMA. (Metcalfe, 1997)  
 
TERMA is an acronym for total energy released per unit mass by an ionising particle. 
It includes the energy from both secondary charged particles and scattered photon 
energy, which is the same as the energy of the incident photon. Thus TERMA is the 
energy lost from the primary beam per unit mass.  
 
Kernels can be obtained from Monte Carlo simulations and show the pattern of 
energy deposition within an array of voxels. Kernels are comprised of either two or 
three components. Firstly there is the primary component for the primary dose and 
then either a scatter component (for first and multiple scatters) or a first scatter 
component and then a multiple scatter component. Because kernels vary in 
inhomogeneous media this is not strictly convolution but superposition.  Kernels also 
account for the change in the transport of scattered radiation due to inhomogeneities. 
Diagram 2.4 shows an energy deposition kernel. 
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Diagram 2.4 – Energy deposition kernels 
 
The collapsed cone convolution method uses an analytical kernel represented by a 
set of cones. The energy deposited from each of these cones is collapsed onto the 
central ray line of each cone, hence it is the collapsed cone convolution method. 
(Butson, 2000) 
 
 
 
Diagram 2.5 – Shows the geometry for convolution calculation methods. (sourced 
from Metcalfe, Kron and Hoban, 1997) 
 
If the energy fluence of primary photons at point r’ is Ψ(r’) then TERMA T(r’) is given 
by: 
 
( ') ( ') ( ')T r r rμρ= Ψ  (4) 
 
where μρ  is the mass attenuation coefficient. 
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For polyenergetic beams the equation needs to be modified to include each energy 
component in the beam spectrum: 
 
1
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Where n is a component of the energy spectrum.   
 
For each point in a unit of mass the attenuation due to the change in depth from the 
surface will be different. : 
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Where ⏐r’-r0⏐ is the geometric depth to point r’.  
 
For an inhomogeneous medium the effective depth needs to be used rather then the 
geometric depth. For divergent beams the inverse square law falloff must also be 
considered.  
 
In the convolution/superposition process, each kernel is modulated by the TERMA to 
obtain the dose at each point. For a homogeneous medium: 
 
3
'
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For an inhomogeneous medium: 
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NB: For homogeneous media, ρ(r) = ρ(r’) and therefore these terms cancel out.  
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For calculation between two points, an average density along the path length can be 
found, creating an effective path length. This can then be used for calculation of the 
energy loss of secondary electrons travelling from r to r’.  
 
'
1 ( '') ''
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ave r
r dr
r r
ρ ρ= − ∫   (9) 
 
This is not strictly correct because electron scattering depends not only on average 
density but also the density distribution but the average density works as an 
approximation.  
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In order to save calculation time where the kernels are spatially invariant, the 
convolution/superposition process can be performed in Fourier space.  
 
D = T ⊗ K   (11) 
 
Where: D is the dose 
T is the TERMA  
  K is the kernel. 
 
ℑ(D) = ℑ(T) x ℑ(K)  (12) 
 
The dose is therefore obtained from the inverse Fourier transform of the 
convolution/superposition performed in Fourier space.  
 
In PinnacleTM both the collapsed cone convolution and adaptive convolution dose 
calculation engines use the same algorithm. For adaptive convolution varying the 
resolution of the dose grid based on a dose gradient difference method, thus 
decreasing the calculation time.   
 
The ADAC PinnacleTM treatment planning system uses a three-dimensional 
collapsed cone convolution algorithm to calculate dose.  It can calculate the effects of 
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patient heterogeneity for both primary and scattered radiation, even in areas of 
perturbed electronic equilibrium, such as tissue air interfaces. This is important for 
lung dose modelling.   
 
For a slab phantom (solid water/lung/solid water) it has been found that data 
calculated from the PinnacleTM TPS and measured data agree within 2% for a field 
size of 5 x 5 cm, at 6 and  10 MV. The method overestimates the dose just beyond 
the lung tissue interface due to charged particles being more laterally deflected than 
predicted by the kernel density scaling method. (Butson, 2000) 
 
 
 
 
Dose Distributions 
 
For megavoltage beams used for TBI there is a predominance of Compton 
interactions (Khan, 1994), which are almost independent of effective atomic number, 
but vary with effective electron density. Hence it can be assumed that the presence 
of an inhomogeneity modifies the photon fluence but not the absorption processes. 
(Sanchez-Nieto, 1997) 
 
For bilateral treatments, the dose uniformity across the patient will be higher for 
higher energy beams as they will penetrate further. Also, increasing the SAD causes 
less dose variation across the patient.  For AP/PA treatments with patient separation 
between 18 and 26 cm most megavoltage treatments will provide dose uniformity 
across the patient within 15%. There will be high non-uniformity for bilateral 
treatments. (AAPM report 17)  
 
The dose distribution may be less uniform for bilateral techniques than the AP/PA 
techniques, especially for larger patients and lower energies, (Syh, 1992) but it can 
be more comfortable for the patient to be able to lie flat for bilateral techniques. 
 
For a four field technique, it has been found that a more homogeneous dose 
distribution will be achieved if approximately two-thirds of the dose is delivered from 
the anterior/posterior fields with the remaining third coming from the lateral fields 
(Cosset, 1994).   
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 Lung Doses 
 
Within the lungs (compared to soft tissue) there is decreased attenuation of photons 
and a loss of scatter (increased ratio of primary to scattered radiation) and, as 
scattered radiation has an increased range, electronic disequilibrium, which results in 
a loss of dose. This effect increases for smaller field sizes and higher energies. Due 
to the higher proportion of primary radiation leaving the lungs, there is an increased 
dose build-up on the exit side of the lungs. (Khan, 2003) 
 
Lung tissue is both radiation sensitive and responsible for many of the potential fatal 
side effects from TBI, this includes radiation pneumonitis. Hence the lung is the main 
critical organ at risk in TBI. The probability of radiation pneumonitis depends on the 
volume of lung irradiated and total dose. A 5% change in lung dose could result in a 
20% change to the probability of a patient developing radiation pneumonitis. (AAPM 
report 17) 
 
Thus the lung dose is important, and lungs are often shielded during TBI treatments, 
especially if the prescribed dose is above lung tolerance. During most lateral TBI 
treatments, the patients will lie with their arms beside them, partially shielding the 
lungs.  
 
Many parameters influence the dose received to the lungs. These factors include 
anatomical factors such as lung size, density and position in the body, position of the 
calculation point and beam quality. (Quast, 1987) 
 
To reduce lung doses, customised lead, cerrobend (bismuth 50%, lead 26%, tin 13% 
and cadmium 11%) or rose metal (bismuth 50%, tin 25% and lead 25%) 
compensators can be used as filters (Harden, 2001, Sanchez-Nieto, 1997, Svahn-
Tapper, 1990). These compensators can be supported on PerspexTM beam spoiler 
screens and can be designed from thoracic radiographs taken with the patient in 
treatment position. Portal films can be taken to confirm location of the compensators. 
If blocks are mounted on the accessory mount rather then on the PerspexTM beam 
spoiler the principle of geometric divergence means that blocks can be made much 
smaller then the organs they are required to protect. However, care should be taken 
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regarding the penumbra around such blocks if they are mounted too far from the 
patient. The compensators can be either present for the entire treatment or just part 
of the treatment.  
 
Compensators can also be designed by calculating the monitor units and dose to 
several different points in the body and then adding layers of lead to make these 
more uniform (Quast, 1986).    
 
If a bilateral technique is used and lung shielding is employed, it should be noted that 
this would reduce the dose to the mediastinum, as this will also be shielded.  
 
Partial transmission shields may also be used to reduce the lung dose without 
completely shielding them, thus also giving dose to the mediastinum.  A similar 
technique involves using shielding blocks for only part of the treatment time. (Khan, 
1994) 
 
Dose Verification  - Phantom Measurements 
 
Dose distribution data can be measured using a phantom. A phantom is a term that 
refers to a material that simulates the radiation absorption and scattering properties 
of the tissue of interest. Simple phantoms are composed of water, which has similar 
radiation absorption properties to muscle and other soft tissues. Other solid materials 
have also been developed with the similar electron density for water for use as 
phantoms in the megavoltage range. (Khan, 2003)  
 
Treatment planning techniques can be evaluated using an anthropomorphic 
phantom. The phantom simulates the patient and can be CT scanned for accurate 
treatment planning. A commercially available anthropomorphic phantom is the 
RANDOTM phantom produced by the Alderson Research Laboratories, Inc. in 
Stamford, Connecticut. This phantom incorporates materials to simulate tissues such 
as muscle, bone, air cavities and lungs, with a similar contour to a typical head, neck 
and torso. (Khan, 2003)  
 
These phantoms allow for close positioning of TLDs and also allow slots for films. 
This allows for dose distributions to be obtained and compared to plans, without 
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distortions from changes in anatomy, but with anatomy that is representative of a real 
patient. Effective organ doses can also be calculated from this data. (Syh, 1992) 
 
For cases where a “standard” patient size is not representative, another humanoid 
phantom technique has been posed where water containers are laid out and filled 
with water to different heights to represent patient thickness at each site (Obcemea, 
1992).  
 
 
 
Dose Verification – Invivo Dosimetry 
 
Due to the complex calculations required to obtain dose distributions and their 
inherent difficulties, combined with clinical issues such as patient movement, invivo 
dosimetry is the optimal way to check the actual dose delivered to the patient (ICRU 
report 24, 1976). It is also important to know the dose delivered to a patient 
accurately for treatment records for comparisons of treatment results, patient 
statistics and to assess side effects.  
 
Commonly used are semiconductor diodes and MOSFETs, ion chambers and 
Lithium Fluoride (LiF) TLDs. These are used to measure exit and entrance doses. 
Depending on the type of dosimeter, the temperature of the dosimeter may need to 
be considered (ie closer to body temperature than room temperature and time for the 
dosimeter to reach thermal equilibrium).  
 
The electrical safety of high voltage dosemeters such as ion chambers also needs to 
be considered during TBI treatments. It is also preferable to have real time results, 
also provided by diodes and mosfets. 
 
The detectors used for invivo dosimetry need to be correctly calibrated and 
commissioned prior to use to ensure optimised reproducibility and accuracy is 
achieved.  
 
Dosimetry data from invivo dosimetry can then be used to modify the number of 
monitor units given per fraction. At some centres (Harden, 2001) the number of 
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monitor units given for the first fraction is standard and the number of monitor units 
for each other fractions is determined only from the results of the invivo dosimetry. 
The dosimetry data can also be used to vary lung compensator lead thickness if 
required to ensure lung is adequately shielded. 
For patients smaller then about 20 cm thickness, an average of the entrance and exit 
doses will give a midline dose with an accuracy of about 1 – 2%. However, for thicker 
patients, the shape of the depth dose curves must be considered to obtain an 
estimate of the midline dose to the patient. (AAPM report 17)   
The dosimeters may measure entrance and exit doses. Dosimeters can also be 
placed along the midline of the patient, eg, between the legs, to determine midline 
dose.  Doses to areas where body thickness varies, such as the feet, head and neck 
can be assessed with invivo dosimetry. Dosimeters around the axillae can assess the 
lateral dose uniformity and aid in assessing lung dose. (AAPM report 17) 
 
Thermolumniscient Dosimetry 
Certain crystalline materials such as lithium fluoride absorb x-ray energy by lifting 
electrons from the valence band to the conduction band and by adding impurities into 
the crystal these electrons then fall into impurity traps in the forbidden zone between 
the valence band and the conduction band.  The electrons in the impurity traps are 
storing energy. This energy is then released when sufficient heat is added to lift these 
trapped electrons back into the conduction band where they can then fall back into 
the valence band, emitting their excess energy as a visible light photon. This process 
is known as thermoluminescence. The light emitted is proportional to the x-ray 
energy absorbed and thus provides a way of measuring absorbed dose.  (Bomford 
and Kunkler, 2003) TLDs are dose rate independent. (ICRU 21) 
Preparation for TLD measurements should also include a standard pre-irradiation 
anneal of 400°C for 1 hour followed by 100°C for 2 hours. The heating cycle for 
reading the chips should be the same as was used for calibration. Both the reader 
and each individual chip should be calibrated. (Amor Duch, 1998) The detectors 
should be surrounded by build up materials to ensure electronic equilibrium.   
After being exposed to radiation the TLDs are read in a specialized “reader”. The 
TLDs are heated to 300°C. The light output is measured using a photomultiplier tube, 
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which converts visible light into an electrical current which can be amplified and 
recorded. The thermoluminescence of a material plotted against temperature is 
called a glow curve. (Bomford and Kunkler, 2003; Kahn, 2003) 
TLDs are a relative dosimeter and require calibration by comparison with other TLDs 
exposed to known doses of radiation of the same quality. (Bomford and Kunkler, 
2003) 
Lithium Fluoride has an effective atomic number of 8.2, which is similar to that of soft 
tissue which has an effective atomic number of 7.4. Lithium Fluoride is almost 
independent of energy in the range typically used in a radiotherapy department. 
(Bomford and Kunkler, 2003) 
 
 
Film Dosimetry 
 
Radiographic film has a cellulose or polyester base coated with an emulsion 
containing silver bromide crystals doped with silver sulphide to make the crystal 
lattice sensitive to visible light and x-ray photons. (Bomford and Kunkler, 2003) 
 
When exposed to radiation, the crystal emulsion undergoes chemical changes 
forming a latent image. The film is developed and the affected crystals become 
smalls grains of metallic silver. During the fixing process, the unaffected crystals are 
removed, leaving clear film in their place. The metallic granules are not affected by 
the fixer so stay in place, darkening the film. (Khan, 2003) 
 
The degree of darkening is thus proportional to how much incident radiation there 
was. So dose is proportional to optical density, OD, defined as: 
 
OD = log Io/I  (13) 
 
Where:  Io is the incident light 
                      I is the transmitted light through the film 
 
With excellent spatial resolution and being capable of dose integration, film is 
suitable dosimeter for practical two dimensional dosimetry. Kodak EDR2 film is 
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commonly used for radiotherapy dosimetry verification as it can accurately measure 
high doses without saturating as it has smaller grains and fewer high Z silver halide 
molecules than other films, reducing its over response to lower energy radiation. 
(Childress, 2005) Kodak EDR2 film has a linear dose response to about 5 Gy. For 
comparison, Kodak XV2 film for therapy verification saturates at about 1 Gy so has a 
very limited linear dose response region. (Dogan 2002) It has been shown to be 
insensitive to dose rate. (Buciolini, 2004).   
 
Delays between exposing and processing EDR2 film can affect its optical density 
response by as much as 4 - 6%.  The optical density response has stabilised to 99% 
of its value by one hour. (Childress, 2004).  
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Chapter Three – Methods   
 
In this chapter I describe how I modified an anthropomorphic phantom. This allowed 
multiple lung sizes to be simulated and the effect that this would have had on the 
effective chest width calculation required for TBI planning. The planning process is 
described, as are the verification techniques.   
 
Phantom design 
 
An anthropomorphic tissue equivalent phantom (RANDO, Alderson labs) was 
modified for this project so that any effects of lung size could be ascertained. The 
phantom is comprised of 2.5 cm thick slices as seen in diagram 3.1. The material 
simulating muscle has a density and effective atomic number similar to muscle so 
radiation interacts with the material in a similar way to muscle. The lung tissue has a 
lower density and closely simulates lungs in the median respiratory state. Higher 
density material is used to simulate the bones. 
 
           
 
Diagram 3.1 – Shows the RANDOTM phantom, both complete and in sections, 
including the slots for TLD placement.   
 
The unmodified RANDOTM phantom was CT scanned allowing visualisation of which 
slices contained low density lung material. All slices containing low density lung 
material were then replaced with PerspexTM slices of the same size with removable 
inserts for lungs (cork) of different sizes. This allowed lung lateral dimensions to be 
varied for the purposes of this study. PerspexTM was used as it simulates muscle 
tissue. Cork was used as it has a low density similar to lung tissue. (ICRU 44 )  
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In the modified phantom, hereafter described as the RANDOTM lung phantom, there 
were four sizes of lung. Starting with the largest lung, 1 cm of cork from the lateral 
surfaces of the lung could be replaced by a 1 cm insert of PerspexTM, providing a 
narrower lung. Similarly, cork could be removed from the anterior and posterior 
surfaces of the lung, and replaced with PerspexTM making the lungs shorter. The 
length of the lungs in the inferior – superior direction could also be changed. Thus 
four lung sizes (largest lung, smallest lung, wide short lung and narrow tall lung) were 
made. This can be seen in diagram 3.2.  
 
 
 
Diagram 3.2 – a slice of the lung insert part of the anthropomorphic phantom 
modification showing the arrangement of the smallest lung on the left, with a cork 
insert surrounded by PerspexTM inserts and the largest lung, with the cork insert from 
the smaller lung arrangement surrounded with cork inserts, as also seen loose on the 
side. 
 
As the area of interest for the phantom verification testing was not near the surface, 
for ease of setup a beam spoiler was not used during either planning or treatment.   
 
Measurements of Phantom 
 
The RANDOTM lung phantom was scanned on a clinical GE HiSpeed CT scanner 
(General Electric Medical Systems, Milwaukee, Wisconsin) dedicated to radiotherapy 
simulation. The physical chest of the width was determined from the CT scan data 
and the width of the hip of the RANDOTM lung phantom was measured physically with 
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callipers. This data is required in the TBI planning process for Monitor Unit 
calculation.  
 
Scout scans were completed first and the lung area was then selected for the helical 
scans. The scans were performed using a chest reconstruction algorithm. They were 
full helical scans, with a pitch of 1, 1 s rotation time and the exposure parameters 
were 120 kV and 130 mA. The slices were each 2 mm thick. 
 
Prescription 
 
The most common prescription at Westmead is 12 Gy in 6 fractions (2 Gy/fraction) 
treated bi-daily with at least 6 hours between each fraction. For some paediatric 
patients the dose rate may also be limited to be below 10 cGy/min at the midplane. 
Together with a smaller dose per fraction this reduces the risk of radiation 
pneumonitis, which is a higher risk in paediatric patients. Dose rate control on a 
linear accelerator can be achieved by varying the continuously variable pulse 
repetition frequency control.   
 
Planning 
 
Two planning systems, RadplanTM and PinnacleTM were used to calculate monitor 
units with heterogeneity corrections turned on and the plan repeated for 
homogeneous conditions, for both primary and scattered radiation.  
 
RadplanTM is a treatment planning system that uses the Bentley – Milan algorithm to 
calculate dose and the Batho method to correct for heterogeneities. It uses a sector 
integration method. 
 
PinnacleTM (ADAC Laboratories, Milpitas, California) is a commercially available 
treatment planning system that uses a convolution method to calculate dose 
distributions for radiotherapy. An adaptive convolution algorithm was used with a 
dose grid of 0.4cm in all directions. This allows for speed of calculations with no 
significant effect on accuracy.   
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Beam Parameters 
 
Two laterally opposed, isocentric and symmetric beams were used. The 6 MV beams 
are from a Varian 6Ex Clinac (Varian Medical Systems Inc, Palo Alto, California) 
using the IEC scaling system. (IEC, 2002) The linear accelerator monitor unit ion 
chamber is absolutely calibrated to provide a machine output of 1.0 cGy/monitor unit 
at machine isocentre following the IAEA TRS 398 protocol. Table 3.1 shows the 
parameter settings used for the beams. For PinnacleTM the isodose distribution was 
also calculated for a 400 cm SAD.  
 
Parameter Settings 
Field size 40 x 40 cm 
Collimator angle 45° 
Gantry angle 90° and 270° 
Couch angle 0° 
  
Table 3.1 – Beam parameters 
 
In the treatment planning systems the treatment was planned at a SAD of 100 cm, as 
beam data was not available at the extended SAD for TBI. The extended SAD is 
accounted for in the treatment monitor units by the inverse square law factor. 
 
Point of Interest and Prescription 
 
A point of interest is added and positioned so that is in the middle of lungs and gives 
an even depth for each beam. The two beams were added with a 50% beam 
weighting. The plan is then calculated, giving the number of monitor units required to 
be delivered for each beam so the prescribed dose is delivered.  
 
In PinnacleTM, the prescription was made to the calculation point and in RadplanTM 
the prescription was made to the isodose line that that passed through the calculation 
point.   
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Repeat Trial for Homogeneous Density Correction 
 
The plan was then repeated but the heterogeneity correction was changed to 
homogeneous for both primary and scattered radiation. The monitor units and 
isodoses were recalculated. This simulates a CT dataset with the same external 
patient contour but with a density of 1 g/cm3, measuring the effects of the 
heterogeneity of the lungs. 
 
Isodose Maps 
 
 
Isodose maps were produced to provide a method for visual evaluation of the dose 
distribution. The isodose maps are displayed in absolute dose. See diagrams 4.4 – 
4.10.  
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Effective Chest Width and Treatment Monitor Unit Calculation 
 
The monitor units for heterogenous and homogeneous plans from both RadplanTM 
and PinnacleTM were then used in conjunction with physical measurements of the 
chest width and hip width to calculate the treatment monitor units and bolus 
requirements from data used for standard planning data.  
 
The ratio between monitor units of corresponding heterogeneous and homogeneous 
plans was used to calculate the effective chest width, by correcting for the 
heterogeneity caused by the lungs. This is achieved by multiplying the ratio by the 
TMR for the equivalent square and depth (based on half the measured distance from 
the left to right axilla). The equivalent square was calculated using the area over 
perimeter method.  
 
Equivalent Square  = 2 H T
H T
× ×
+    (14) 
 
Where  H = patient height and 
    T = patient thickness at hips.  
 
Ratio = homogeneous monitor units/heterogeneous monitor units 
 
TMR(S, eff) = TMR(S, m)  x ratio  (15) 
 
Where  TMR(S, eff) = the TMR for the equivalent field size S and the 
effective depth 
  
 TMR(S, m)  = the TMR for the equivalent field size S and half the 
measured distance between the left and right axilla.   
 
The effective depth can be found from the TMR tables. Because the point is at 
midline, doubling his value gives the effective axilla to axilla distance.  
 
The patients lay with their arms beside their chest within the TBI cradle, so the 
PerspexTM sides of the cradle and the patient’s arms need to be included in the 
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effective chest width used for calculations (this was not the case for RANDOTM, as 
RANDOTM has no arms and for the verification measurements no PerspexTM screen 
was used). During the initial patient measurements, a chest width measurement is 
taken, which includes the total chest width. This was corrected using the difference 
between the measured and effective distance between axillae. The effective chest 
with is thus calculated: 
 
(Ws)eff = Ws – (d-deff)  (16) 
 
 
Where  (Ws)eff = the effective chest width 
 
   Ws = the measured chest width 
 
   d = measured distance between axillae 
 
   deff = effective distance between axillae 
 
As the hip width is always larger than the effective chest width for both phantoms 
used, the hip width is used to calculate the monitor units for treatment and bolus is 
placed around the chest for treatment. The extra bolus placed around each side of 
the chest is half the difference between the hip width and effective chest width.  
 
If the hip width was smaller than the effective chest width the depth used for monitor 
unit calculation would be half the effective chest width and bolus would be around the 
patient’s hips.  
 
The bolus material used for treatment is small bags filled with rice. Around the head 
and neck region extra PerspexTM is added to the side of the TBI cradle so the 
effective width is the of the head is the same of the width used for calculation. Bolus 
is wrapped around the patient’s neck to bring the neck width to the same as the head 
width.  
 
Half the hip width is thus used as the depth to which the monitor units are calculated, 
to give the prescribed dose to the midline of the patient. However, for the verification 
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measurements, the effective chest width was used and no bolus was added as the 
measurement were taken around the chest region.  
 
The monitor units are calculated using the following formula: 
 
100 (10)
( / 2, ) ( , ) ( )
D PSFMU
TMR P S AAF x y PSF S ISL
× ×= × × ×    (17) 
 
Where D = prescribed dose per fraction multiplied by the beam weighting for 
each field 
 
 PSF(10) = phantom scatter factor for a 10 x 10 cm field size 
 
 TMR(P/2,S) = tissue maximum ratio for the depth (half hip width) and 
equivalent square size S 
 
 AAF(x,y) = air area factor for collimator jaw setting (a collimator scatter 
factor). 
 
 PSF(S) = phantom scatter factor for equivalent field size S 
 
 ISL – inverse square law correction for the extended SAD of 400 cm 
 
The inverse square law is: 
 
ISL = 
22
400
100100 ⎟⎠
⎞⎜⎝
⎛=⎟⎠
⎞⎜⎝
⎛
SAD
    (18) 
 
Phantom Verification – TLDs  
 
Using calculations completed on the unmodified RANDOTM phantom, a plan was 
developed using RadplanTM to treat the phantom with TLDs so the dose per monitor 
unit could be measured.  
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There were many reasons why TLDs were chosen as the detector for this 
application. These included their small size, which enabled them to fit into slots within 
the RANDOTM phantom. TLDs have no cables attached, reusable and cost effective 
and have good long-term stability and negligible environmental (temperature, 
pressure, humidity) factors. 
 
For the TLD measurements, the number of monitor units to be delivered was based 
on the effective chest width using the ratio from the homogeneous and 
inhomogeneous monitor units from the RadplanTM planning system and rather than 
using the hip width for calculating the monitor units and then adding bolus as would 
be done for treatment, as the aim was to assess the effective chest width calculation. 
 
The TLDs used were Harshaw TLD-100 chips, which are lithium fluoride chips doped 
with impurities of magnesium and titanium. The chips have a physical size of 3.2 x 
3.2 x 0.89 mm and a density of 2.64 g/cm3 and a Zeff of 8.2. The TLDs are always 
handled with vacuum tweezers.  
 
Prior to use, the TLD system was calibrated according to the Westmead Hospital 
clinical protocol. A reader calibration factor (RCF) was generated using a special 
calibration set of TLDs. The RCF factor is the ratio of response of the instrument in 
nanocoloumbs to the actual radiation to which the calibration dosimeters were 
exposed, i.e. converting the readings from nC to cGy. 
 
The set of TLDs used was a set of clinical TBI TLDs, calibrated for 2 Gy exposures. 
Each TLD set in the chip was given an individual element correction coefficient 
(ECC).  The ECC for each dosimeter corrects its response to produce a response 
equal to the average of all the dosimeters, as not all chips can be manufactured with 
the same TL efficiency. 
 
The TLD chips were calibrated in a PerspexTM phantom with holes drilled in it for 
TLDs and Farmer style ion chamber placement. Ion chamber readings are corrected 
for temperature and pressure. Conditions for calibrations should be as close as 
possible to the conditions for TLD measurement, including using beams with the 
same beam quality as for measurement and approximately 2 Gy being delivered to 
both treatment and calibration chips to reduce supralinearity effects.  
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 Before calibration and exposure measurements, TLDs are pre-annealed for one hour 
at 400°C and then for two hours at 100°C. This also removes residual TL signals and 
establishes TLD sensitivity.  
 
The TLDs are placed into slots within the RANDOTM phantom especially designed for 
TLD chips. Chips were placed into three slots on midplane about the calculation point 
used in the planning systems. Diagram 3.3 shows red crosses where the TLDs were 
positioned. It should be noted that there is some uncertainty introduced as the 
calculation point was in the middle of the slice whereas TLDs are to be positioned 
towards the edge of the slice.  
 
 
 
Diagram 3.3 – Placement of the TLDs at the red crosses.  
 
The phantom was positioned on a special TBI treatment couch at an extended FAD 
of 4 metres as planned. The phantom was treated according to the plan, rotating the 
phantom after each beam. (The bunker is wider on one side of the gantry than the 
other, so rather then rotating the gantry to deliver the bilateral beams, the patient bed 
is rotated). The phantom was aligned using a special TBI laser that points down a 
line that is 4 metres from the source. This laser line was aligned to the midline of the 
phantom. This process was repeated three times for three sets of TLDs and the 
results averaged.  
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Some of the set of TLDs were reserved and are now used for scaling purposes for 
supralinearity correction. The scaling dose is based on an estimate of what the dose 
to the TLDs in the phantom was. The scaling is done in the calibration phantom, 
together with an ion chamber to measure absolute dose. The ion chamber reading 
was corrected for air density and other factors such as polarity.  
 
After irradiation, fading occurs in TLDs, particularly in peaks not used for dosimetry. 
In order to hasten the fading process, TLDs are post annealed for 10 minutes at 
100°C prior to being read.  
 
The automatic Harshaw 5500 reader was used. The TLDs are read with an 
acquisition set up of a temperature ramp of 15°C/s to a maximum of 300°C with an 
acquisition time of 33 1/3 seconds.   
 
The results from the reader are transferred as an ASCII file to a Microsoft Excel 
worksheet with a macro developed using Visual Basic for Applications to use the 
reading from the scaling TLDs and a supralinearity corrections formula (fitted to 
measured supralinearity curve) to correct the measured TLDs.  
 
Phantom Verification – Film  
 
Radiographic film was used as a two dimensional dosimeter to verify the dose 
distributions produced by the treatment planning systems and the differences from 
changing to the extended SAD used for treatment. Radiochromic film could also have 
been used, but radiographic film was more cost effective and available in larger 
sheets.  
 
A sheet of ready-packed Kodak EDR2 film (Eastman Kodak Company, Rochester, 
New York) from the same batch as the films used for phantom verification was used 
for calibration. It was exposed to varying amounts of radiation using a 6 MV beam 
from a Varian 6Ex Clinac from 0.25 Gy to 4 Gy, as calculated using measured 
treatment planning data. 5 cm of solid water was used for backscatter and 1.5 cm of 
solid water was placed on top of the film. Each segment of radiation had a field size 
of 5 x 5 cm. The film was positioned at an SAD of 100 cm. 
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One envelope of ready-packed Kodak EDR2 film was positioned between slices of 
the anthropomorphic phantom close to the calculation point used by the treatment 
planning systems. The phantom slices were clamped together and were positioned at 
TBI treatment position (TBI extended SAD of 400 cm) and 1966 monitor units were 
delivered bilaterally, as per calculations based on heterogeneity correction for the 
RANDOTM phantom produced by PinnacleTM, based a prescription of 2 Gy per 
fraction. The film was removed and another film positioned and the phantom 
repositioned so that the SAD was 100 cm. 123 monitor units were delivered 
bilaterally.  
 
Pin pricks were made in one corner of each film to mark the orientation of the film 
and to allow for air pockets to be squeezed out of the pre packaged film envelopes to 
prevent hot spots developing.  
 
The films were left overnight to stabilise its optical density response. The film 
envelopes were opened in the darkroom and each film was processed in an AGFA 
classic E.O.S. automatic film processor, dedicated to use for radiotherapy films. All 
the films were processed sequentially in the same batch to reduce processor 
variation. 
 
Following being processed the films were digitised using a VXR-16 Dosimetry Pro 16 
bit CCD film scanner (VIDAR Systems Corporation, Herndon Virginia) and the 
images were saved in TIFF image format.  
 
These tiff image files were then loaded into the DoseLab 3.05 software (Childress, 
2003) for analysis. The software calculates the dose at a point as being proportional 
to the optical density of the film.  
 
The calibration film was used to convert optical density to dose. The films from the 
100 cm and 400 cm SAD phantom verification measurements were then converted to 
dose and isodoses were calculated for comparison with the isodose distributions 
produced by the treatment planning systems.  
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Chapter Four – Results 
 
CT to density calibration 
  
Diagram 4.1 shows the calibration of Hounsfield unit (HU) to density used by 
PinnacleTM and RadplanTM. 
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Diagram 4.1 – the Hounsfield calibration for density used by the planning systems. 
The PinnacleTM system uses CT numbers so these have been converted to 
Hounsfield number for display.  
 
Ratio Differences: RadplanTM and PinnacleTM
 
Table 4.1 shows the effective chest widths calculated using the ratio between 
heterogeneous and homogenous monitor units from PinnacleTM and RadplanTM and 
the difference between the two models. The systematic difference arises because 
PinnacleTM includes the effects of changes to scatter due to the heterogeneity. If the 
effective chest width is larger than the hip width, bolus is added around the hips so 
the effective chest width and the hip width are the same.   
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 PinnacleTM 
effective chest 
width (cm) 
RadplanTM 
effective chest 
width (cm) 
Difference  
Wide Short 20.8 20.1 3.4%
Narrow Tall 22.8 21.9 3.9%
Largest Lung 20.7 20.1 2.9%
Smallest Lung 22.7 21.9 3.5%
RANDOTM  22.6 21.9 3.1%
 
Table 4.1 – The effective chest widths calculated using the ratios between 
heterogeneity and homogeneity calculations from PinnacleTM and RadplanTM for 
different phantoms.   
 
Table 4.2 shows the dose per monitor unit calculated using the effective chest width 
based on the ratio of homogeneous and inhomogeneous monitor units calculations 
produced by the treatment planning system together with the average dose per 
monitor unit as measured by TLDs. The standard deviation for the TLD 
measurements was ±4%, so both the PinnacleTM and RadplanTM dose delivered per 
monitor unit agree within one standard deviation with the measured dose per monitor 
unit.   
 
Calculation/measurement technique Dose (Gy) per monitor unit at 400 cm 
SAD 
RadplanTM 0.105 
PinnacleTM 0.102 
TLD 0.106 
 
Table 4.2 – Dose (Gy) per monitor unit at the extended TBI SAD of 400 cm as 
calculated using the ratios from RadplanTM and PinnacleTM and measured using 
TLDs.  
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Film Dose Response 
 
Diagram 4.2 shows the exposed film used to determine the dose response curve and 
diagram 4.3 shows the dose response curve obtained from the film and used for film 
to dose calibration.   
 
 
 
Diagram 4.2 – the calibration film used to convert optical density to dose.  
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Diagram 4.3 – the calibration curve used to convert optical density to dose. 
 
 
Isodose Distributions 
 
All diagrams are normalised so that 100% of the prescribed dose is at the calculation 
point on central axis midline.  
 
Diagram 4.4 shows the isodose distribution produced by PinnacleTM for the 
RANDOTM phantom in the transverse plane containing the calculation point, marked 
by the orange cross on the isodose map. Diagram 4.5 shows the same thing for 
RadplanTM. Diagram 4.6 shows the measured isodose distribution from the Kodak 
EDR2 film at an SAD of 100 cm in RANDOTM, showing at least a reasonable 
qualitative agreement with diagrams 4.4 and 4.5. It can be seen that the measured 
dose as in diagram 4.6 receives a slightly higher dose in the centre of the chest than 
either system calculated and shows better agreement with the distribution calculated 
by PinnacleTM. 
 
Diagram 4.7 shows the measured isodose distribution from Kodak EDR2 film at an 
SAD of 400 cm in RANDOTM and diagram 4.8 shows the calculated isodose 
distribution at 400 cm SAD from PinnacleTM.   
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Diagram 4.4  – isodose distribution in the transverse plane at 100 cm SAD calculated 
by PinnacleTM.  
 
 
 
Diagram 4.5 – isodose distribution in the transverse plane at 100 cm SAD calculated 
by RadplanTM
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Diagram 4.6 – measured isodose distribution from film at and SAD of 100 cm in 
RANDOTM. 
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Diagram 4.7  – measured isodose distribution from film at extended SAD of 400 cm 
in RANDOTM. 
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Diagram 4.8 – RANDOTM PinnacleTM isodose distribution with heterogeneity 
correction at 400 cm SAD. 
 
 
 
Diagram 4.9 – RANDOTM PinnacleTM isodose distribution without heterogeneity 
correction at 100 cm SAD.  
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Diagram 4.10 – RANDOTM RadPlanTM isodose distribution without heterogeneity 
correction at 100 cm SAD.  
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Chapter five – Discussion  
 
TBI involves complex dosimetry but the dosimetry due to the large SAD, dose 
uniformity and flatness over the large field, bolus requirements, extra scatter from the 
bunker walls and floor and large field overshoot. There is also a lack of specialised 
treatment planning systems for TBI planning at extended SAD.  
 
TBI involves complex dosimetry due to the large SAD. This changes the angular 
distribution and electron contamination of the beam, changing the dose uniformity 
and flatness over the large field. TBI dosimetry is also complex due to bolus 
requirements, extra scatter from the bunker walls and floor and large field overshoot. 
There is also a lack of specialised treatment planning systems for TBI planning at 
extended SAD.  
 
In this project the effective chest width for treatment monitor unit calculations and 
bolus requirements was calculated. This value varies between the 2D Bentley – 
Milan algorithm with modified Batho heterogeneity corrections and the 3D 
convolution method by less than 4%.  The width of the lungs caused the greatest 
variation. Changing the height and depth of the lungs produced less than 1% 
variation.  
 
Having determined the difference between RadplanTM and PinnacleTM does not 
change significantly due to lung size, the phantom verification work was completed 
using RANDOTM, as TLD slots were available to position the TLDs. One 
disadvantage with the RANDOTM phantom is it doesn’t have arms, which would affect 
the dose distributions delivered in a real patient, as the arms would provide additional 
shielding to the lungs. Hence TLDs were placed in RANDOTM and the measurements 
showed that the dose per monitor unit using an effective chest width for monitor unit 
calculations using the ratio between heterogeneity and homogeneity calculations 
from RadplanTM and PinnacleTM varied less than 4%. According to the AAPM TG53 
report, the recommended accuracy required in calculations from a treatment planning 
system for a 3D calculation with heterogeneities present should be within 5%. This 
shows that either method of calculating the effective chest width could be used for 
calculating the number of monitor units for TBI treatments.  
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 Each method also provides some isodose display information, although PinnacleTM 
can display this information on all transverse slices as well as sagittal and coronal 
views.  
 
The sagittal and coronal views show the small air gaps between phantom slices that 
would not be present in a patient and that RadplanTM would not have included in its 
calculations. These gaps would not have been perfectly reproduced during each TLD 
verification measurement, but it is unlikely this would have much effect on the results, 
especially since the results were averaged over three simulated treatments.  
  
In order to compare the two treatment planning systems the CT calibration curves 
had to be compared. For densities lower than water/tissue equivalent, RadplanTM and 
PinnacleTM calibration of density to Hounsfield number was almost the same. 
However, some discrepancies can be seen with higher density materials which may 
create some small changes between the two treatment planning systems for 
RANDOTM due to the presence of bone. However, the ratio results for RANDOTM are 
consistent with the RANDO lung phantom. These differences are due to changes in 
the CT scanner between commissioning RadplanTM and PinnacleTM, but were not 
significant enough to change the calibration curve in RadplanTM. 
 
Another difference between RadplanTM and PinnacleTM is that the beam data for 
RadplanTM and PinnacleTM was collected at different times. Also, RadplanTM directly 
uses the measured PDD and beam profile data to calculate the dose distribution 
whereas PinnacleTM uses a PDD to determine the beam energy spectrum and uses 
this to model the dose distribution. The same beam data is used for heterogeneity 
and homogeneity plans, so the ratio would cancel some of the differences from 
different beam data measurements or models.  
 
For verification TLDs placed in three locations for each simulated treatment so the 
results of each three chips for each simulation could be averaged together, as well as 
over three simulations. However, as the chips covered a wider area and were not all 
surrounded by the 100% isodose, the TLD readings may vary slightly from 100% of 
dose/monitor unit. Another uncertainty inherent in the TLD positioning is that the 
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calculation point was in the middle of the slice but the TLDs were placed in slots at 
the edge of the slice. 
 
TLDs are not as accurate as ion chambers but have the advantage of being able to 
be placed directly into the phantom and without concern over cable and stem 
irradiation. An ion chamber was not used in this project for verification, as there was 
nowhere to position it.  
 
TLDs are relative dosimeters so the accuracy is determined by reproducibility. In this 
work the reproducibility of the TLD absorbed dose measurements had a standard 
deviation of 4%. This error included errors due to setup for TBI treatment, such as 
phantom positioning and accelerator variation. 
 
The TLDs were scaled with the scaling chips being exposed directly after the 
simulated TBI treatments. This should have helped the reproducibility by cancelling 
out TLD batch sensitivity changes, reader changes, oven changes and accelerator 
output. The calibrations for ECC and RCF were also completed under similar 
conditions to increase reproducibility.  
 
Kodak EDR2 film was also used as a planar dosimeter for verification of the isodose 
distributions produced by the treatment planning systems. A dose response curve 
was generated to ensure the films were exposed to radiation in the linear region of 
the dose response curve and to be used for optical density to dose calibration.  Film 
response to radiation is not the same across the entire film and this could result in up 
to a 2% variation in the response of the film. (Williams and Thwaites, 1993) The film 
was also slightly smaller than the RANDOTM phantom as can be seen in the phantom 
verification films in diagrams 4.6 and 4.7.  
 
Kodak EDR2 film has previously been shown to have variations of less than 2% 
compared to ion chambers except for larger field sizes and greater depth (>15 cm) 
where errors in the range of 3-5% were reported (Chetty, 2002). Thus, particularly 
around the calculation point for TBI treatments, the dose accuracy for the film may be 
lower. Film also has some angular dependence and when exposed parallel to the 
beam, as in the calibration, rather than perpendicular to the beam, some over 
response may be seen. (Suchowerska, 2001) 
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 As expected, changing the height of the lungs makes no difference to the monitor 
units calculated by RadplanTM for the midplane as RadplanTM is a 2D system. There 
was also no significant difference in the ratios when changing the height of the lungs 
in PinnacleTM. This is because the calculation point is out the range of the main 
scattered radiation from the edges of the lungs. The width of the lung made a 
difference for the heterogeneous calculations for both the 2D and 3D system. 
Because no significant variation in the ratios was observed, all further work focussed 
only the smallest lungs and largest lungs.   
 
When the ratios are used to manually calculate the doses required to treat a patient 
with the RANDOTM lung phantom dimensions, because the effective chest width 
always remains smaller than the width of the hip, the monitor units for treatment 
remain the same. However, the plate separation would be different and hence 
different amounts of bolus material would be added to build up the chest to the plate 
separation width. This means that for cases where the effective chest width is smaller 
than the width of the hips for both methods of calculating the ratio for the effective 
chest width (RadplanTM and PinnacleTM), the only part of the body that receives a 
different dose would be the chest, due to the changes in bolus material added.    
 
Isodose distributions from different planning methods and measurements can be 
quantitatively compared. Various methods for quantitative analysis of isodose 
distributions include dose differences or distance to agreement analysis, which 
combines both dose differences and distance to agreement. However, the software 
options available during this project did not allow quantitative analysis of isodose 
maps, so the isodose distribution maps were only visually compared.   
 
The isodose distributions on transverse plane around the calculation point are similar 
between RadplanTM and PinnacleTM but show some differences, especially anterior 
and posterior to the lungs, as the Bentley – Milan algorithm does not calculate 
differences in scatter from heterogeneities. 
 
It is observed that there are differences in the isodose distributions between 
RadplanTM and PinnacleTM even for homogeneous cases. This shows differences 
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between the two calculation methods, such as RadplanTM not calculating the change 
in scatter due to changes in patient contour.  
 
When comparing the results between the smallest lungs and largest lungs in the 
RANDOTM lung phantom the doses are higher around the calculation pt in the largest 
lungs case. This effect is seen more in PinnacleTM, showing an increase in the scatter 
component from the extra lung volume not calculated in RadplanTM. This is also why 
it is the midplane dose is higher in heterogeneous cases than homogeneous cases.  
 
During treatment of patients, patient positioning changes, involuntary and voluntary 
patient motion (including breathing with changes to lung volume), changes to patient 
size and bolus distribution between fractions add to the potential errors of TBI 
treatment. Hence invivo dosimetry is critical during TBI treatments.  
 
In the future it is possible that computer improvements, such as treatment planning 
computers being able to accept larger CT imaging data sets and having increased 
computation speeds, will aid 3D planning for TBI. The difference in measured 
isodose distributions between 100 and 400 cm SAD also suggests that using beam 
data from an extended SAD would be a future improvement so isodoses and DVHs 
can be more accurately used for dose evaluation if required during TBI.  
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Chapter Six – Conclusion 
 
This project compared two planning methods for calculating the heterogeneity 
correction required for determining the effective chest width for planning TBI, taking 
into account possible effects of different lung sizes. The two planning methods were 
the 2D Bentley – Milan algorithm with modified Batho heterogeneity corrections and 
3D convolution planning methods. Measurements were made in an anthropomorphic 
phantom with films and TLDs to verify the results.   
 
An anthropomorphic phantom was modified with different lung size inserts and four 
different lung sizes were calculated on both treatment planning systems. The process 
was repeated using the unmodified anthropomorphic phantom, which had slots for 
TLD measurements for verification measurements.  
 
For an isocentric treatment, the treatment planning system for each lung size 
calculated the monitor units required to deliver the prescribed dose to the midline for 
both with and without heterogeneity corrections.  
 
The ratio between the number of monitor units required with and without 
heterogeneity corrections was used to calculate the effective chest width of the 
patient. This was compared to the measured hip width and the larger value was used 
to calculate the monitor units required to deliver the prescribed dose to the midline at 
TBI treatment SAD.  The effective chest width varied less than 4%.  
 
The effect of different lung sizes was only seen where the width of the lungs 
changed. Changes to the height or depth of the lungs had no significant effect on the 
calculations of the effective chest width, as was to be expected as changing the 
height and depth of the lungs only changes the scatter component. 
 
The isodose distributions in the transverse plane were also measured with Kodak 
EDR2 film and showed reasonable agreement between the calculated and measured 
isodoses at isocentre. The isodose distribution changed significantly at the extended 
TBI treatment SAD of 400 cm. However, the changes showed a more uniform dose 
distribution at the extended SAD, as expected. 
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 The dose per monitor unit at treatment SSD was then calculated for the TBI 
treatment SSD without any bolus or tissue compensation based on the effective 
chest width from both planning systems and this was compared to a dose per 
monitor unit value measured in RANDOTM using TLDs.  
 
Whilst the heterogeneity corrections were different between the planning systems, 
The difference was smaller than one standard deviation of measurements from the 
TLDs, so no significant difference could be detected between each planning method 
and the TLD measurements, which had an accuracy of 4%. This is within the 5% 
accuracy required. The isodose distributions produced by both treatment planning 
systems showed reasonable agreement with the isodose measurements taken at 
isocentre. This shows that either method of planning TBI would be suitable for clinical 
purposes. 
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